Single/Multiple Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY1101042 Given as 5 mg MR Tablet After Single Oral Dosing Followed by Once Daily Dosing for 7 Days in 12 Healthy Male Subjects Per Dose Step in a Randomized, Placebo Controlled, Single Blind, Group Comparison Design
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs BAY 1101042 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Bayer
- 16 Aug 2019 Status changed from active, no longer recruiting to completed.
- 17 Jul 2019 Planned End Date changed from 28 Jun 2019 to 17 Jul 2019.
- 17 May 2019 Planned End Date changed from 17 Jun 2019 to 28 Jun 2019.